- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02876770
Melatonin Supplementation and Performance (MSP)
18 de agosto de 2016 atualizado por: kais
Nocturnal Melatonin Ingestion Ameliorates Short Term Maximal Performances on the Following Day
The present study aimed to evaluate the possible effect of nocturnal melatonin ingestion upon short-term performances, on the following morning.
Twelve soccer players from a Tunisian squad (22.9 ±1.3 years, 1.80±0.05
m, and 72.0±8.8 kg) were volunteered to perform three testing sessions, with one test session per day.
During each session, MEL (5mg) , MEL (8mg) or placebo were ingested, in a randomized order, before nocturnal sleep.
The next morning (08:00h), participants performed the following psycho-cognitive and physical tests: Hooper's index, reaction time, vigilance, handgrip strength , squat jump , modified agility test , Wingate anaerobic test (peak power , mean power and fatigue index ).
Rating of perceived exertion was recorded immediately after the WanT, and blood lactate measures were taken after 3min of recovery.
Blood glucose was measured before and 3 min after the Wingate test.
Visão geral do estudo
Status
Rescindido
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
12
Estágio
- Fase inicial 1
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
20 anos a 23 anos (Adulto)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Macho
Descrição
Inclusion Criteria:
The participants were recruited based on the following criteria: (i) paticipants must be trained at 4-6 days per week for an average of 2 h daily and (ii) they must have at least 8 years of training experience
Exclusion Criteria:
- Subjects were excluded from the study if they present one of the following criteria : heart failure, antioxidant supplementation within 3 months before the study, lower-limb injuries
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
|
|
Experimental: Melatonina
|
Our protocol was composed of three experimental sessions.
During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal.
Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hooper's index score
Prazo: At 07:30 am in the following day of the supplementation
|
Hooper's index score was measured using a specific questionnaire
|
At 07:30 am in the following day of the supplementation
|
|
handgrip strength (in Kg)
Prazo: At 07:30 am in the following day of the supplementation
|
handgrip strength was measured using a calibrated hand dynamometer.
|
At 07:30 am in the following day of the supplementation
|
|
Blood lactate (µmol/l)
Prazo: Blood lactate was measured only 3 minutes after physical testing in the following day of the supplementation
|
Lactate level was measured using Lactate Pro instrument.
|
Blood lactate was measured only 3 minutes after physical testing in the following day of the supplementation
|
|
reaction time (in secondes)
Prazo: At 07:30 am in the following day of the supplementation
|
Reaction time was measured using an electronic timing device.
|
At 07:30 am in the following day of the supplementation
|
|
vigilance score
Prazo: At 07:30 am in the following day of the supplementation
|
Vigilance score was measured using a specific questionnaire
|
At 07:30 am in the following day of the supplementation
|
|
squat jump (in centimeters)
Prazo: At 07:30 am in the following day of the supplementation
|
Squat jump was assessed using a infrared jump system
|
At 07:30 am in the following day of the supplementation
|
|
agility (in secondes)
Prazo: At 07:30 am in the following day of the supplementation
|
Agility was assessed using an electronic timing system.
|
At 07:30 am in the following day of the supplementation
|
|
anaerobic capacity (In watts)
Prazo: At 07:30 am in the following day of the supplementation
|
Anaerobic capacity was assessed using a calibrated friction-loaded cycle ergometer
|
At 07:30 am in the following day of the supplementation
|
|
glucose level (µmol/l)
Prazo: At 07:30 am in the following day of the supplementation (rest condition) and 3 minutes after physical testing in each experimental session
|
Glucose level was assessed using a glucometer
|
At 07:30 am in the following day of the supplementation (rest condition) and 3 minutes after physical testing in each experimental session
|
|
Rating of perceived exertion score
Prazo: Rating of perceived exertion score was measured 3 minutes after physical testing in the following day of the supplementation
|
Rating of perceived exertion score was measured using a specific questionnaire
|
Rating of perceived exertion score was measured 3 minutes after physical testing in the following day of the supplementation
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de dezembro de 2012
Conclusão Primária (Real)
1 de janeiro de 2013
Conclusão do estudo (Real)
1 de janeiro de 2013
Datas de inscrição no estudo
Enviado pela primeira vez
2 de agosto de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
18 de agosto de 2016
Primeira postagem (Estimativa)
24 de agosto de 2016
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
24 de agosto de 2016
Última atualização enviada que atendeu aos critérios de controle de qualidade
18 de agosto de 2016
Última verificação
1 de agosto de 2016
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CNMSS1
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .